Charles Schwab’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$394M Buy
9,223,151
+52,971
+0.6% +$2.88M 0.05% 286
2026
Q1
$575M Buy
9,170,180
+223,677
+3% +$17.9M 0.09% 188
2025
Q4
$853M Buy
8,946,503
+104,190
+1% +$10.2M 0.13% 128
2025
Q3
$863M Buy
8,842,313
+122,402
+1% +$12.7M 0.14% 125
2025
Q2
$937M Buy
8,719,911
+143,697
+2% +$14.5M 0.16% 105
2025
Q1
$865M Buy
8,576,214
+101,183
+1% +$10.2M 0.16% 108
2024
Q4
$757M Buy
8,475,031
+456,654
+6% +$40.2M 0.14% 122
2024
Q3
$672M Buy
8,018,377
+64,720
+0.8% +$5.1M 0.13% 136
2024
Q2
$613M Buy
7,953,657
+61,283
+0.8% +$4.49M 0.12% 148
2024
Q1
$541M Buy
7,892,374
+197,648
+3% +$12.7M 0.12% 139
2023
Q4
$445M Buy
7,694,726
+51,892
+0.7% +$2.77M 0.11% 149
2023
Q3
$404M Buy
7,642,834
+201,008
+3% +$10.5M 0.12% 148
2023
Q2
$403M Sell
7,441,826
-87
-0% -$4.54K 0.11% 151
2023
Q1
$372M Sell
7,441,913
-73,342
-1% -$3.46M 0.11% 151
2022
Q4
$348M Buy
7,515,255
+147,478
+2% +$6.39M 0.11% 164
2022
Q3
$285M Sell
7,367,777
-397,617
-5% -$16M 0.1% 181
2022
Q2
$289M Sell
7,765,394
-34,661
-0.4% -$1.41M 0.1% 187
2022
Q1
$345M Buy
7,800,055
+245,797
+3% +$10.7M 0.1% 175
2021
Q4
$321M Buy
7,554,258
+194,378
+3% +$8.17M 0.09% 187
2021
Q3
$319M Buy
7,359,880
+709,180
+11% +$31.4M 0.1% 172
2021
Q2
$284M Buy
6,650,700
+165,670
+3% +$6.97M 0.09% 187
2021
Q1
$251M Sell
6,485,030
-465,971
-7% -$17.6M 0.09% 192
2020
Q4
$250M Buy
6,951,001
+537,768
+8% +$19.4M 0.1% 187
2020
Q3
$245M Buy
6,413,233
+150,843
+2% +$5.81M 0.11% 168
2020
Q2
$220M Buy
6,262,390
+232,804
+4% +$8.38M 0.11% 179
2020
Q1
$197M Buy
6,029,586
+76,349
+1% +$2.98M 0.12% 169
2019
Q4
$269M Buy
5,953,237
+117,260
+2% +$4.91M 0.14% 127
2019
Q3
$237M Buy
5,835,977
+181,062
+3% +$7.67M 0.14% 136
2019
Q2
$243M Buy
5,654,915
+119,294
+2% +$4.59M 0.15% 126
2019
Q1
$212M Buy
5,535,621
+81,194
+1% +$3.1M 0.14% 137
2018
Q4
$193M Buy
5,454,427
+130,886
+2% +$4.75M 0.15% 124
2018
Q3
$205M Buy
5,323,541
+39,933
+0.8% +$1.39M 0.14% 135
2018
Q2
$173M Buy
5,283,608
+128,310
+2% +$3.87M 0.13% 152
2018
Q1
$141M Buy
5,155,298
+246,223
+5% +$6.69M 0.11% 176
2017
Q4
$122M Buy
4,909,075
+187,773
+4% +$5.18M 0.1% 197
2017
Q3
$138M Buy
4,721,302
+61,729
+1% +$1.7M 0.12% 158
2017
Q2
$129M Sell
4,659,573
-634,350
-12% -$16.8M 0.12% 162
2017
Q1
$132M Sell
5,293,923
-109,612
-2% -$2.67M 0.13% 145
2016
Q4
$117M Buy
5,403,535
+20,138
+0.4% +$439K 0.13% 144
2016
Q3
$128M Buy
5,383,397
+1,582,054
+42% +$37.7M 0.15% 127
2016
Q2
$88.8M Buy
3,801,343
+312,934
+9% +$6.77M 0.11% 173
2016
Q1
$65.6M Buy
3,488,409
+61,239
+2% +$1.08M 0.09% 240
2015
Q4
$63.2M Sell
3,427,170
-62,816
-2% -$1.13M 0.09% 229
2015
Q3
$57.3M Sell
3,489,986
-2,778
-0.1% -$47.5K 0.08% 236
2015
Q2
$61.8M Sell
3,492,764
-629,363
-15% -$11.2M 0.09% 231
2015
Q1
$73.2M Buy
4,122,127
+73,372
+2% +$1.16M 0.1% 194
2014
Q4
$53.6M Buy
4,048,755
+191,642
+5% +$2.45M 0.08% 243
2014
Q3
$45.6M Sell
3,857,113
-341,930
-8% -$4.31M 0.08% 249
2014
Q2
$53.6M Sell
4,199,043
-427,138
-9% -$5.55M 0.09% 216
2014
Q1
$62.5M Buy
4,626,181
+66,620
+1% +$874K 0.11% 188
2013
Q4
$54.8M Sell
4,559,561
-458,469
-9% -$5.42M 0.1% 189
2013
Q3
$59M Sell
5,018,030
-56,594
-1% -$612K 0.12% 172
2013
Q2
$47.5M Buy
+5,074,624
New +$43M 0.11% 191

Other funds holding BSX

Charles Schwab's BSX Position: Q2 2026 in Review

Charles Schwab increased its Boston Scientific (BSX) stake by 0.58% in Q2 2026, buying an estimated $2.88M and bringing the position to 9,223,151 shares worth $394M. The position accounts for 0.05% of the portfolio, ranked #286.

Charles Schwab first reported a position in BSX in Q2 2013 and has held it in 53 quarters since. The position peaked at $937M in Q2 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Charles Schwab held 9,223,151 shares of Boston Scientific worth $394M as of Q2 2026.
  • Charles Schwab bought 52,971 Boston Scientific shares in Q2 2026, an estimated $2.88M.
  • Boston Scientific made up 0.05% of Charles Schwab's portfolio in Q2 2026, its #286 holding.
  • Charles Schwab first reported a position in Boston Scientific in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Boston Scientific position peaked at $937M in Q2 2025.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.